AuntMinnieEurope

Cancer Target

New PET tracer show promise in neuroblastoma

F-18 mFBG achieved a pooled sensitivity of 97%, compared with 82% for I-123 MIBG.

Featured

Who's paying, and for what, is the question that actually decides whether AI in healthcare gets funded.

The cost of AI, and finding its breakeven point

Experts at the Royal College of Radiologists’ 2nd Annual Global AI Conference discussed how AI could help move cancer care toward more personalized treatment, from targeted radionuclide therapy dosing to drug discovery.

AI aims to decode targeted radiotherapy response

Dr. Rowland Illing, chief medical officer at Amazon Web Services (AWS) and a former interventional radiologist.

RCR: Agentic AI is off the leash, and already a workhorse for health systems

July 7, 2026

European Parliament, Brussels. Policymakers, clinicians, and patient representatives at the 'Imaging Saves Lives' event, July 2.

99% wasn't enough: How persistence in imaging changes the picture

July 6, 2026

A visual abstract of the study.

PET/MRI can reduce the need for biopsies in prostate cancer

July 2, 2026

The Safe Hearts Plan aims to shift healthcare systems toward prevention, earlier diagnosis, and more personalized care.

Imaging takes center stage in Europe's Safe Hearts Plan

July 2, 2026

Check out our Cases of the Week!

40-year-old man with right hip finding revisited

A 40-year-old man presented for follow-up imaging at an outpatient imaging center, with right hip trauma a few months prior and a suspicious finding from a recent emergency department (ED) visit.

22-year-old woman with neck swelling revisited

26-year-old man with multiple gunshot wounds and abdominal trauma revisited

Cancer Target

New PET tracer show promise in neuroblastoma

99% wasn't enough: How persistence in imaging changes the picture

PET/MRI can reduce the need for biopsies in prostate cancer

Imaging takes center stage in Europe's Safe Hearts Plan

AuntMinnieEurope.com CT Insider

Who's paying, and for what, is the question that actually decides whether AI in healthcare gets funded.

The cost of AI, and finding its breakeven point

AI aims to decode targeted radiotherapy response

RCR: Agentic AI is off the leash, and already a workhorse for health systems

Most patients want to know if AI being used for imaging reports

More work than relief: AI in the wrong seat, RCR census finds

Blue Earth, UCL dose first patient in Ac-225 PSMA prostate trial

Philips launches new ultrasound system

Imagion extends collaboration with Siemens on MRI contrast agent

Median gets CE marking for lung cancer screening software

Quibim launches AI breast MRI tool across Europe, UK

Blue Earth, UCL dose first patient in Ac-225 PSMA prostate trial

By AuntMinnie.com staff writers

The study is evaluating an investigational alpha-emitting PSMA-targeted radiopharmaceutical in prostate cancer patients.

July 9, 2026

Philips launches new ultrasound system

By AuntMinnie.com staff writers

The system features AI-powered workflows and is designed for high-volume clinical environments.

July 8, 2026

Imagion extends collaboration with Siemens on MRI contrast agent

By AuntMinnie.com staff writers

Siemens will provide in-kind expertise and technical support to clinical sites.

July 8, 2026

Median gets CE marking for lung cancer screening software

By AuntMinnie.com staff writers

The CE marking follows the U.S. Food and Drug Administration (FDA)'s 510(k) clearance of eyonis LCS in February.

July 6, 2026

Quibim launches AI breast MRI tool across Europe, UK

By AuntMinnieEurope.com staff writers

The tool, QP-Breast, highlights suspicious areas on MRI and generates reports from imaging findings.

July 2, 2026

Qp Breast Press 02

GE HealthCare, University Hospital Essen open nuclear medicine center

By AuntMinnieEurope.com staff writers

The center features the first installation of GE HealthCare's StarGuide GX SPECT/CT scanner.

July 1, 2026

Can side-chain chemistry help radiologists choose a safer contrast agent after a hypersensitivity reaction?

By Claudia Tschabuschnig

Choosing an alternative contrast agent after an allergic reaction often falls to clinical judgment. A new review examines whether side-chain chemistry can make that decision a little more evidence based.

July 1, 2026

Dr. Aart J. van der Molen, of Leiden University Medical Center in Leiden, the Netherlands, is the lead author of a review exploring side-chain chemistry as a guide for selecting alternative iodine-based contrast media.

Most patients want to know if AI being used for imaging reports

By Amerigo Allegretto

Most patients want disclosure about whether AI is being used for their imaging reports.

June 30, 2026

Patient Cancer Doctor 400 (1)

Low muscle density on coronary CT linked to heart risk

Patients with skeletal muscle attenuation below the median had a higher risk of mortality and myocardial infarction.

June 30, 2026

An example of machine learning–based multiorgan body composition assessment (TotalSegmentator V2.0.4, 1.5-mm high-resolution model) in a 63-year-old man with obstructive coronary artery disease and a skeletal muscle attenuation below the median. (A) Transverse, (B) coronal, and (C) sagittal CT images and curved planar reformations of the (D) left, (E) circumflex, and (F) right coronary arteries.

Medneo acquires Ramsay Diagnostics UK mobile imaging fleet

By AuntMinnieEurope.com staff writers

Medneo is acquiring Ramsay Diagnostics UK's mobile MRI and CT fleet and a six-year contract to provide mobile imaging services.

June 30, 2026

Mri Scanner2 400

Ratio Therapeutics signs Ac-225 supply agreement with PanTera

By AuntMinnie.com staff writers

Deal will support Ratio's alpha therapy programs.

June 30, 2026

Business Deal Corporate 400

More work than relief: AI in the wrong seat, RCR census finds

By Claudia Tschabuschnig

AI adoption is climbing fast across U.K. radiology and cancer services, but put in the wrong room, it creates more noise than signal.

June 29, 2026

AI adoption is growing across UK imaging and cancer services, but workforce shortages persist-